These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23692381)

  • 61. qPCR and qRT-PCR analysis: Regulatory points to consider when conducting biodistribution and vector shedding studies.
    Ma H; Bell KN; Loker RN
    Mol Ther Methods Clin Dev; 2021 Mar; 20():152-168. PubMed ID: 33473355
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Hepatotoxicity and Toxicology of
    Kaiser RA; Nicolas CT; Allen KL; Chilton JA; Du Z; Hickey RD; Lillegard JB
    Hum Gene Ther Clin Dev; 2019 Jun; 30(2):57-66. PubMed ID: 30860398
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recent Progress in Gene Therapy for Ovarian Cancer.
    Áyen Á; Jiménez Martínez Y; Marchal JA; Boulaiz H
    Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966369
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A Low Protein Binding Cationic Poly(2-oxazoline) as Non-Viral Vector.
    He Z; Miao L; Jordan R; S-Manickam D; Luxenhofer R; Kabanov AV
    Macromol Biosci; 2015 Jul; 15(7):1004-20. PubMed ID: 25846127
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer.
    Sallinen H; Heikura T; Koponen J; Kosma VM; Heinonen S; Ylä-Herttuala S; Anttila M
    BMC Cancer; 2014 Sep; 14():696. PubMed ID: 25245329
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Antiangiogenic gene therapy with soluble VEGF-receptors -1, -2 and -3 together with paclitaxel prolongs survival of mice with human ovarian carcinoma.
    Sopo M; Anttila M; Sallinen H; Tuppurainen L; Laurema A; Laidinen S; Hamalainen K; Tuunanen P; Koponen JK; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
    Int J Cancer; 2012 Nov; 131(10):2394-401. PubMed ID: 22336998
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Cotargeting of VEGFR-1 and -3 and angiopoietin receptor Tie2 reduces the growth of solid human ovarian cancer in mice.
    Sallinen H; Anttila M; Gröhn O; Koponen J; Hämäläinen K; Kholova I; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
    Cancer Gene Ther; 2011 Feb; 18(2):100-9. PubMed ID: 20865022
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antiangiogenic gene therapy with soluble VEGFR-1, -2, and -3 reduces the growth of solid human ovarian carcinoma in mice.
    Sallinen H; Anttila M; Narvainen J; Koponen J; Hamalainen K; Kholova I; Heikura T; Toivanen P; Kosma VM; Heinonen S; Alitalo K; Yla-Herttuala S
    Mol Ther; 2009 Feb; 17(2):278-84. PubMed ID: 19050699
    [TBL] [Abstract][Full Text] [Related]  

  • 69. A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
    Buller RE; Runnebaum IB; Karlan BY; Horowitz JA; Shahin M; Buekers T; Petrauskas S; Kreienberg R; Slamon D; Pegram M
    Cancer Gene Ther; 2002 Jul; 9(7):553-66. PubMed ID: 12082455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth.
    Ebos JM; Lee CR; Bogdanovic E; Alami J; Van Slyke P; Francia G; Xu P; Mutsaers AJ; Dumont DJ; Kerbel RS
    Cancer Res; 2008 Jan; 68(2):521-9. PubMed ID: 18199548
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Preclinical safety, toxicology, and biodistribution study of adenoviral gene therapy with sVEGFR-2 and sVEGFR-3 combined with chemotherapy for ovarian cancer.
    Tuppurainen L; Sallinen H; Kokki E; Koponen J; Anttila M; Pulkkinen K; Heikura T; Toivanen P; Hämäläinen K; Kosma VM; Heinonen S; Alitalo K; Ylä-Herttuala S
    Hum Gene Ther Clin Dev; 2013 Mar; 24(1):29-37. PubMed ID: 23692381
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications.
    Horowitz J
    Curr Opin Mol Ther; 1999 Aug; 1(4):500-9. PubMed ID: 11713766
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Promising new drugs in the treatment of ovarian cancer, and of gynecologic tumors, in general].
    Di Leo A
    Tumori; 1999; 85(3 Suppl 1):S27-9. PubMed ID: 10542883
    [No Abstract]   [Full Text] [Related]  

  • 74.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.